0000000000331956

AUTHOR

A. Schmidt‐glintzer

showing 1 related works from this author

Epidural ropivacaine -- where are the benefits? A prospective, randomized, double-blind trial in patients with retropubic prostatectomy.

2007

Background:  In comparison with bupivacaine, ropivacaine exhibits comparable anaesthetic effects but with less motor impairment and systemic toxicity. However, the analgesic potency may differ. For example, ropivacaine during obstetric epidural analgesia provides an approximately 40% lower analgesic potency than bupivacaine. Equal visual analogue pain scores require significantly higher dosages of ropivacaine, and general statements about a favourable benefit–risk profile relative to that of bupivacaine may therefore have limited clinical impact. We addressed this topic in a male pain model by evaluating the analgesic efficacy of epidural ropivacaine 0.2% vs. bupivacaine 0.125% after retrop…

Malemedicine.medical_specialtyTime FactorsDosemedicine.drug_classAnalgesicMotor ActivityStatistics NonparametricLumbarDouble-Blind MethodClinical endpointmedicineHumansRopivacaineProspective StudiesEpidural administrationAnesthetics LocalAgedPain MeasurementBupivacaineProstatectomyPain Postoperativebusiness.industryRopivacaineLocal anestheticAnalgesia Patient-ControlledGeneral MedicineMiddle AgedAmidesBupivacaineSurgeryAnalgesia EpiduralAnesthesiology and Pain MedicinePatient SatisfactionAnesthesiabusinessmedicine.drugActa anaesthesiologica Scandinavica
researchProduct